Julie R. Nangia

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Rachel A. Freedman, Rebecca Gelman, Carey K. Anders et al. · Journal of Clinical Oncology · 2019 · 338 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer

Julie R. Nangia, Tao Wang, Cynthia Osborne et al. · JAMA · 2017 · 229 citations

Medicine, Dermatology, Oncology +13

TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders et al. · Clinical Cancer Research · 2019 · 154 citations · Full text

Medicine, Oncology, Pharmacology +17

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Meenakshi Anurag, Eric J. Jaehnig, Karsten Krug et al. · Cancer Discovery · 2022 · 139 citations · Full text

Life Sciences, Molecular Biology, Oncology +17